Circulating lamin B1 (LMNB1) biomarker detects early stages of liver cancer in patients

Journal of Proteome Research

Volumn 9, Issue 1, 2010, Pages 70-78

  Sun, Stella ^a   Xu, Michelle Z ^a   Poon, Ronnie T ^a   Day, Philip J ^b   Luk, John M ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Circulating mRNA; Early HCC; Proteomic profiling; Tumor marker

Indexed keywords

BIOLOGICAL MARKER; LAMIN B; LAMIN B1; PROTEOME; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CANCER SIZE; CANCER STAGING; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIAGNOSTIC VALUE; EARLY DIAGNOSIS; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LIVER CELL CARCINOMA; LUNG NODULE; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; UPREGULATION;

ADULT; ANALYSIS OF VARIANCE; FEMALE; HUMANS; LAMIN TYPE B; LIVER NEOPLASMS; MALE; MIDDLE AGED; REPRODUCIBILITY OF RESULTS; RNA, MESSENGER; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 73649104101     PISSN: 15353893     EISSN: None     Source Type: Journal    
DOI: 10.1021/pr9002118     Document Type: Article

References (41)

1. Jemal, A.; Siegel, R.; Ward, E.; Murray, T.; Xu, J.; Thun, M. J. Cancer statistics, 2007. CA Cancer J. Clin. 2007, 57 (1), 43-66.
2. Kamangar, F.; Dores, G. M.; Anderson, W. F. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J. Clin. Oncol. 2006, 24 (14), 2137-50.
3. Poon, R. T.; Fan, S. T. Hepatectomy for hepatocellular carcinoma: patient selection and postoperative outcome. Liver Transplant. 2004, 10 (2 Suppl. 1), S39-45.
4. Lai, E. C.; Lau, W. Y. The continuing challenge of hepatic cancer in Asia. Surgeon 2005, 3 (3), 210-5.
5. Chan, A. C.; Poon, R. T.; Ng, K. K.; Lo, C. M.; Fan, S. T.; Wong, J. Changing paradigm in the management of hepatocellular carcinoma improves the survival benefit of early detection by screening. Ann. Surg. 2008, 247 (4), 666-73.
6. Lau, W. Y.; Lai, E. C. Hepatocellular carcinoma: current management and recent advances. Hepatobiliary Pancreatic Dis. Int. 2008, 7 (3), 237-57.
7. Okuda, K.; Ohtsuki, T.; Obata, H.; Tomimatsu, M.; Okazaki, N.; Hasegawa, H.; Nakajima, Y.; Ohnishi, K. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985, 56 (4), 918-28.
8. Collier, J.; Sherman, M. Screening for hepatocellular carcinoma. Hepatology 1998, 27 (1), 273-8.
9. Sun, S.; Lee, N. P.; Poon, R. T.; Fan, S. T.; He, Q. Y.; Lau, G. K.; Luk, J. M. Oncoproteomics of hepatocellular carcinoma: from cancer markers' discovery to functional pathways. Liver Int. 2007, 27 (8), 1021-38.
10. Aravalli, R. N.; Steer, C. J.; Cressman, E. N. Molecular mechanisms of hepatocellular carcinoma. Hepatology 2008, 48 (6), 2047-63.
11. Pang, R. W.; Joh, J. W.; Johnson, P. J.; Monden, M.; Pawlik, T. M.; Poon, R. T. Biology of hepatocellular carcinoma. Ann. Surg. Oncol. 2008, 15 (4), 962-71.
12. Greene, F. L. P. D.; Fleming, I. D.; Fritz, A. G.; Balch, C. M.; Haller, D. G. AJCC Cancer Staging Manual, 6th ed.; Springer: Chicago, IL, 2002; pp 131-144.
13. Wong, B. W.; Luk, J. M.; Ng, I. O.; Hu, M. Y.; Liu, K. D.; Fan, S. T. Identificationofliver-intestinecadherininhepatocellularcarcinoma - a potential disease marker. Biochem. Biophys. Res. Commun. 2003, 311 (3), 618-24.
14. Lee, N. P.; Leung, K. W.; Cheung, N.; Lam, B. Y.; Xu, M. Z.; Sham, P. C.; Lau, G. K.; Poon, R. T.; Fan, S. T.; Luk, J. M. Comparative proteomic analysis of mouse livers from embryo to adult reveals an association with progression of hepatocellular carcinoma. Proteomics 2008, 8 (10), 2136-49.
15. Luk, J. M.; Lam, C. T.; Siu, A. F.; Lam, B. Y.; Ng, I. O.; Hu, M. Y.; Che, C. M.; Fan, S. T. Proteomic profiling of hepatocellular carcinoma in Chinese cohort reveals heat-shock proteins (Hsp27, Hsp70, GRP78) up-regulation and their associated prognostic values. Proteomics 2006, 6 (3), 1049-57.
16. Lee, N. P.; Chen, L.; Lin, M.; Tsang, F.; Yeung, C.; Poon, R.; Peng, J.; Leng, X.; Beretta, L.; Sun, S.; Day, P.; Luk, J. M. Proteomic Expression Signature Distinguishes Cancerous and Non-Malignant Tissues in Hepatocellular Carcinoma. J. Proteome Res. 2009, 8 (3), 1293-1303.
17. Yi, X.; Luk, J. M.; Lee, N. P.; Peng, J.; Leng, X.; Guan, X. Y.; Lau, G. K.; Beretta, L.; Fan, S. T. Association of mortalin (HSPA9) with liver cancer metastasis and prediction for early tumor recurrence. Mol. Cell. Proteomics 2008, 7 (2), 315-25.
18. Wang, Y. Q.; Luk, J. M.; Ikeda, K.; Man, K.; Chu, A. C.; Kaneda, K.; Fan, S. T. Regulatory role of vHL/HIF-1alpha in hypoxia-induced VEGF production in hepatic stellate cells. Biochem. Biophys. Res. Commun. 2004, 317 (2), 358-62.
19. Mok, B. W.; Yeung, W. S.; Luk, J. M. Differential expression of gap-junction gene connexin 31 in seminiferous epithelium of rat testes. FEBS Lett. 1999, 453 (3), 243-8.
20. Wang, X. Q.; Luk, J. M.; Leung, P. P.; Wong, B. W.; Stanbridge, E. J.; Fan, S. T. Alternative mRNA splicing of liver intestine-cadherin in hepatocellular carcinoma. Clin. Cancer Res. 2005, 11 (2 Pt 1), 483-9.
21. Moisan, E.; Girard, D. Cell surface expression of intermediate filament proteins vimentin and lamin B1 in human neutrophil spontaneous apoptosis. J. Leukocyte Biol. 2006, 79 (3), 489-98.
22. Ikoma, J.; Kaito, M.; Ishihara, T.; Nakagawa, N.; Kamei, A.; Fujita, N.; Iwasa, M.; Tamaki, S.; Watanabe, S.; Adachi, Y. Early diagnosis of hepatocellular carcinoma using a sensitive assay for serum desgamma-carboxy prothrombin: a prospective study. Hepatogastroenterology 2002, 49 (43), 235-8.
23. Henry, L.; Lavabre-Bertrand, T.; Vercambre, L.; Ramos, J.; Carillo, S.; Guiraud, I.; Pouderoux, P.; Bismuth, M.; Valats, J. C.; Demattei, C.; Duny, Y.; Chaze, I.; Funakoshi, N.; Bureau, J. P.; Daures, J. P.; Blanc, P. Plasma proteasome level is a reliable early marker of malignant transformation of liver cirrhosis. Gut 2009, 58 (6), 833-8.
24. Zinkin, N. T.; Grall, F.; Bhaskar, K.; Otu, H. H.; Spentzos, D.; Kalmowitz, B.; Wells, M.; Guerrero, M.; Asara, J. M.; Libermann, T. A.; Afdhal, N. H. Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin. Cancer Res. 2008, 14 (2), 470-7.
25. Miura, N.; Maruyama, S.; Oyama, K.; Horie, Y.; Kohno, M.; Noma, E.; Sakaguchi, S.; Nagashima, M.; Kudo, M.; Kishimoto, Y.; Kawasaki, H.; Hasegawa, J.; Shiota, G. Development of a novel assay to quantify serum human telomerase reverse transcriptase messenger RNA and its significance as a tumor marker for hepatocellular carcinoma. Oncology 2007, 72 Suppl 1, 45-51.
26. Fan, A. C.; Deb-Basu, D.; Orban, M. W.; Gotlib, J. R.; Natkunam, Y.; O'Neill, R.; Padua, R. A.; Xu, L.; Taketa, D.; Shirer, A. E.; Beer, S.; Yee, A. X.; Voehringer, D. W.; Felsher, D. W. Nanofluidic proteomic assay for serial analysis of oncoprotein activation in clinical specimens. Nat. Med. 2009, 15 (5), 566-71.
27. Yung, T. K.; Chan, K. C.; Mok, T. S.; Tong, J.; To, K. F.; Lo, Y. M. Single-molecule detection of epidermal growth factor receptor mutations in plasma by microfluidics digital PCR in non-small cell lung cancer patients. Clin. Cancer Res. 2009, 15 (6), 2076-84.
28. Lim, S. O.; Park, S. J.; Kim, W.; Park, S. G.; Kim, H. J.; Kim, Y. I.; Sohn, T. S.; Noh, J. H.; Jung, G. Proteome analysis of hepatocellular carcinoma. Biochem. Biophys. Res. Commun. 2002, 291 (4), 1031-7.
29. Kopreski, M. S.; Benko, F. A.; Kwak, L. W.; Gocke, C. D. Detection of tumor messenger RNA in the serum of patients with malignant melanoma. Clin. Cancer Res. 1999, 5 (8), 1961-5.
30. Chen, X. Q.; Bonnefoi, H.; Pelte, M. F.; Lyautey, J.; Lederrey, C.; Movarekhi, S.; Schaeffer, P.; Mulcahy, H. E.; Meyer, P.; Stroun, M.; Anker, P. Telomerase RNA as a detection marker in the serum of breast cancer patients. Clin. Cancer Res. 2000, 6 (10), 3823-6.
31. Cheung, S. T.; Fan, S. T.; Lee, Y. T.; Chow, J. P.; Ng, I. O.; Fong, D. Y.; Lo, C. M. Albumin mRNA in plasma predicts post-transplant recurrence of patients with hepatocellular carcinoma. Transplantation 2008, 85 (1), 81-7.
32. Dechat, T.; Pfleghaar, K.; Sengupta, K.; Shimi, T.; Shumaker, D. K.; Solimando, L.; Goldman, R. D. Nuclear lamins: major factors in the structural organization and function of the nucleus and chromatin. Genes Dev. 2008, 22 (7), 832-53.
33. Tang, C. W.; Maya-Mendoza, A.; Martin, C.; Zeng, K.; Chen, S.; Feret, D.; Wilson, S. A.; Jackson, D. A. The integrity of a lamin-B1-dependent nucleoskeleton is a fundamental determinant of RNA synthesis in human cells. J. Cell Sci. 2008, 121 (Pt 7), 1014-24.
34. Chiarini, A.; Whitfield, J. F.; Pacchiana, R.; Armato, U.; Dal Pra, I. Photoexcited calphostin C selectively destroys nuclear lamin B1 in neoplastic human and rat cells - a novel mechanism of action of a photodynamic tumor therapy agent. Biochim. Biophys. Acta 2008, 1783 (9), 1642-53.
35. Malhas, A. N.; Lee, C. F.; Vaux, D. J. Lamin B1 controls oxidative stress responses via Oct-1. J. Cell Biol. 2009, 184 (1), 45-55.
36. Fiume, R.; Ramazzotti, G.; Teti, G.; Chiarini, F.; Faenza, I.; Mazzotti, G.; Billi, A. M.; Cocco, L. Involvement of nuclear PLCbeta1 in lamin B1 phosphorylation and G2/M cell cycle progression. FASEB J. 2009, 23 (3), 957-66.
37. Goldberg, M. W.; Fiserova, J.; Huttenlauch, I.; Stick, R. A new model for nuclear lamina organization. Biochem. Soc. Trans. 2008, 36 (Pt 6), 1339-43.
38. Dynlacht, J. R.; Earles, M.; Henthorn, J.; Seno, J. D. Different patterns of DNA fragmentation and degradation of nuclear matrix proteins during apoptosis induced by radiation, hyperthermia or etoposide. Radiat. Res. 2000, 154 (5), 515-30.
39. Silva, J. M.; Rodriguez, R.; Garcia, J. M.; Munoz, C.; Silva, J.; Dominguez, G.; Provencio, M.; Espana, P.; Bonilla, F. Detection of epithelial tumour RNA in the plasma of colon cancer patients is associated with advanced stages and circulating tumour cells. Gut 2002, 50 (4), 530-4.
40. Wong, S. C.; Lo, S. F.; Cheung, M. T.; Ng, K. O.; Tse, C. W.; Lai, B. S.; Lee, K. C.; Lo, Y. M. Quantification of plasma beta-catenin mRNA in colorectal cancer and adenoma patients. Clin. Cancer Res. 2004, 10 (5), 1613-7.
41. Salway, F.; Day, P. J.; Ollier, W. E.; Peakman, T. C. Levels of 5′ RNA tags in plasma and buffy coat from EDTA blood increase with time. Int. J. Epidemiol. 2008, 37 (Suppl. 1), i11-5.